Skip to main content
. 2020 Sep;12(9):4643–4650. doi: 10.21037/jtd-19-3790

Figure 3.

Figure 3

Overall survival (OS) for patients with metastatic NSCLC with uncommon EGFR mutation, after exclusion of those with p.Leu858Arg co-mutation. Point estimate (continuous line) and 95% CI (discontinuous line) are shown.